Royalty Pharma (RPRX) Income from Continuing Operations (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Income from Continuing Operations data on file, last reported at 468256000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations rose 7.79% year-over-year to 468256000.0; the trailing twelve-month figure through Mar 2026 stood at 1359015000.0 (down 23.2% YoY), and the FY2025 full-year result was 1324192000.0, changed 0.5% from the prior year.
• Income from Continuing Operations improved to 468256000.0 in Q1 2026, from 355913000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 806358000.0 in Q3 2024 to a low of 610030000.0 in Q4 2022.
• A 5-year average of 297318411.76 and a median of 351336000.0 in 2023 frame the typical range for Income from Continuing Operations.
• Across the five-year window, Income from Continuing Operations slumped 1236.61% in 2022 and soared 10266.93% in 2025, its largest moves.
• Tracing RPRX's Income from Continuing Operations over 5 years: stood at 610030000.0 in 2022, then soared by 217.63% to 717586000.0 in 2023, then slumped by 53.41% to 334351000.0 in 2024, then grew by 6.45% to 355913000.0 in 2025, then surged by 31.56% to 468256000.0 in 2026.
• Business Quant data shows RPRX's Income from Continuing Operations at 468256000.0 in Q1 2026, 355913000.0 in Q4 2025, and 444211000.0 in Q3 2025.